KDR and ovarian carcinoma: We elected to use conjugates 1–3 in this endeavor considering that (i) the integrin-recognizing moiety could ensure cell-selective accumulation on αVβ3-overexpressing ovarian carcinoma cells and possibly provide internalization via integrin-mediated endocytosis, (ii) once entered the cells, the sunitinib moiety could be available to exert its intracellular inhibitory effect, and (iii) the overall conjugates could alter the αVβ3-VEGFR2 crosstalk thus impacting the downstream intracellular pathways related to these receptors [18,19].